HBcrAg predicts hepatocellular carcinoma development: An analysis using time-dependent receiver operating characteristics

Lai, 2003, Viral hepatitis B, Lancet, 362, 2089, 10.1016/S0140-6736(03)15108-2 Lavanchy, 2004, Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures, J Viral Hepat, 11, 97, 10.1046/j.1365-2893.2003.00487.x Beasley, 1981, Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22,707 men in Taiwan, Lancet, 2, 1129, 10.1016/S0140-6736(81)90585-7 Szmuness, 1978, Hepatocellular carcinoma and the hepatitis B virus: evidence for a causal association, Prog Med Virol, 24, 40 Rustgi, 1987, Epidemiology of hepatocellular carcinoma, Gastroenterol Clin North Am, 16, 545, 10.1016/S0889-8553(21)00328-9 Kiyosawa, 2004, Hepatocellular carcinoma: recent trends in Japan, Gastroenterology, 127, S17, 10.1053/j.gastro.2004.09.012 Chen, 1997, Epidemiological characteristics and risk factors of hepatocellular carcinoma, J Gastroenterol Hepatol, 12, S294, 10.1111/j.1440-1746.1997.tb00513.x Hsu, 2002, Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B, Hepatology, 35, 1522, 10.1053/jhep.2002.33638 Kao, 2000, Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B, Gastroenterology, 118, 554, 10.1016/S0016-5085(00)70261-7 Yuen, 2009, Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B, J Hepatol, 50, 80, 10.1016/j.jhep.2008.07.023 Kato, 2001, Determination of hepatitis B virus genotype G by polymerase chain reaction with hemi-nested primers, J Virol Methods, 98, 153, 10.1016/S0166-0934(01)00374-3 Suzuki, 2009, Correlation between serum hepatitis B virus core-related antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patients, J Med Virol, 81, 27, 10.1002/jmv.21339 Matsumoto, 2007, Low serum level of hepatitis B core-related antigen indicates unlikely reactivation of hepatitis after cessation of lamivudine therapy, Hepatol Res, 37, 661, 10.1111/j.1872-034X.2007.00094.x Hosaka, 2010, HBcrAg is a predictor of post-treatment recurrence of hepatocellular carcinoma during antiviral therapy, Liver Int, 30, 1461, 10.1111/j.1478-3231.2010.02344.x Lok, 2009, Chronic hepatitis B: update 2009, Hepatology, 50, 661, 10.1002/hep.23190 2012, EASL clinical practice guidelines: management of chronic hepatitis B virus infection, J Hepatol, 57, 167, 10.1016/j.jhep.2012.02.010 Liaw, 2012, Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update, Hepatol Int, 6, 531, 10.1007/s12072-012-9365-4 Hosaka, 2013, Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection, Hepatology, 58, 98, 10.1002/hep.26180 Kumada, 2013, Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: a propensity score analysis, J Hepatol, 58, 427, 10.1016/j.jhep.2012.10.025 Heagerty, 2005, Survival model predictive accuracy and ROC curves, Biometrics, 61, 92, 10.1111/j.0006-341X.2005.030814.x Lin, 2013, Heavy alcohol consumption increases the incidence of hepatocellular carcinoma in hepatitis B virus-related cirrhosis, J Hepatol, 58, 730, 10.1016/j.jhep.2012.11.045 Li, 2014, The diagnostic value of the FIB-4 index for staging hepatitis B-related fibrosis: a meta-analysis, PLoS One, 9 Kim, 2010, Validation of FIB-4 and comparison with other simple noninvasive indices for predicting liver fibrosis and cirrhosis in hepatitis B virus-infected patients, Liver Int, 30, 546, 10.1111/j.1478-3231.2009.02192.x 2010, Hepatol Res, 40, 6, 10.1111/j.1872-034X.2010.00652.x Bruix, 2005, Management of hepatocellular carcinoma, Hepatology, 42, 1208, 10.1002/hep.20933 Bruix, 2011, Management ofhepatocellular carcinoma: an update, Hepatology, 53, 1020, 10.1002/hep.24199 Kimura, 2003, New enzyme immunoassay for detection of hepatitis B virus core antigen (HBcAg) and relation between levels of HBcAg and HBV DNA, J Clin Microbiol, 41, 1901, 10.1128/JCM.41.5.1901-1906.2003 Wong, 2007, Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection, J Clin Microbiol, 45, 3942, 10.1128/JCM.00366-07 Liu, 2004, Evolution of precore/core promoter mutations in hepatitis B carriers with hepatitis B e antigen seroreversion, J Med Virol, 74, 237, 10.1002/jmv.20176 Kao, 2000, Hepatitis B genotypes and the response to interferon therapy, J Hepatol, 33, 998, 10.1016/S0168-8278(00)80135-X Tseng, 2012, High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load, Gastroenterology, 142, 1140, 10.1053/j.gastro.2012.02.007 Chen, 2006, REVEAL-HBV Study Group. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level, JAMA, 295, 65, 10.1001/jama.295.1.65 Chan, 2011, Hepatitis B surface antigen quantification: why and how to use it in 2011 – A core group report, J Hepatol, 55, 1121, 10.1016/j.jhep.2011.06.006 Tseng, 2013, Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads, Hepatology, 57, 441, 10.1002/hep.26041 Kusakabe, 2011, A population-based cohort study for the risk factors of HCC among hepatitis B virus mono-infected subjects in Japan, J Gastroenterol, 46, 117, 10.1007/s00535-010-0307-4 Jung, 2015, Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients, J Gastroenterol Kanda, 2013, Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics, Bone Marrow Transplant, 48, 452, 10.1038/bmt.2012.244 2014, Drafting Committee for Hepatitis Management Guidelines and the Japan Society of Hepatology. JSH guidelines for the management of hepatitis B virus infection, Hepatol Res, 44, 1, 10.1111/hepr.12269 Kimura, 2002, Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load, J Clin Microbiol, 40, 439, 10.1128/JCM.40.2.439-445.2002 Honda, 2015, HBcrAg during nucleos(t)ide analog therapy are related to intra-hepatic HBV replication and development of hepatocellular carcinoma, J Infect Dis Yang, 2008, Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma, J Natl Cancer Inst, 100, 1134, 10.1093/jnci/djn243 Liu, 2006, Role of hepatitis B viral load and basal core promoter mutation in hepatocellular carcinoma in hepatitis B carriers, J Infect Dis, 193, 1258, 10.1086/502978 Chou, 2008, Temporal relationship between hepatitis B virus enhancer II/basal core promoter sequence variation and risk of hepatocellular carcinoma, Gut, 57, 91, 10.1136/gut.2006.114066 Tseng, 2015, Higher proportion of viral basal core promoter mutant increases the risk of liver cirrhosis in hepatitis B carriers, Gut, 64, 292, 10.1136/gutjnl-2014-306977 Teli, 1995, Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver, Lancet, 346, 987, 10.1016/S0140-6736(95)91685-7 Bellentani, 1997, Drinking habits as cofactors of risk for alcohol induced liver damage. The Dionysos Study Group, Gut, 41, 845, 10.1136/gut.41.6.845